{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:05Z","timestamp":1793119625692,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007470","name":"Shaqra University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007470","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014786","name":"Northern Border University","doi-asserted-by":"publisher","award":["NBU-CRP-2025-2043"],"award-info":[{"award-number":["NBU-CRP-2025-2043"]}],"id":[{"id":"10.13039\/501100014786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jiph.2025.102873","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T13:58:34Z","timestamp":1750255114000},"page":"102873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of tocilizumab in COVID-19: A systematic evaluation of adverse effects and therapeutic outcomes"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3800-6825","authenticated-orcid":false,"given":"Othman","family":"AlOmeir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1427-032X","authenticated-orcid":false,"given":"Ahmad H.","family":"Alhowail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Imam","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1533-9667","authenticated-orcid":false,"given":"Syed Mohammed Basheeruddin","family":"Asdaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafiulla","family":"Gilkaramenthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abida","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-1040","authenticated-orcid":false,"given":"Mohd","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9929-5739","authenticated-orcid":false,"given":"Tafadzwa","family":"Dzinamarira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2025.102873_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","article-title":"New biological therapies for multiple myeloma","volume":"75","author":"Garfall","year":"2024","journal-title":"Annu Rev Med"},{"issue":"17","key":"10.1016\/j.jiph.2025.102873_bib2","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.3390\/ijms23179604","article-title":"Monoclonal antibody engineering and design to modulate FcRn activities: a comprehensive review","volume":"23","author":"Ramdani","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jiph.2025.102873_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","article-title":"Advances in antibody-based therapy in oncology","volume":"4","author":"Zinn","year":"2023","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.jiph.2025.102873_bib4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/07388551.2020.1869684","article-title":"Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development","volume":"41","author":"Kaur","year":"2021","journal-title":"Crit Rev Biotechnol"},{"issue":"3","key":"10.1016\/j.jiph.2025.102873_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13311-022-01224-9","article-title":"Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management","volume":"19","author":"Krajnc","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.jiph.2025.102873_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jiph.2025.102873_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2023.116472","article-title":"The impact of social media influencers on health outcomes: systematic review","volume":"340","author":"Powell","year":"2024","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jiph.2025.102873_bib8","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.13219","article-title":"Burden of COVID-19: a preliminary analysis in the population of Saudi Arabia","volume":"10","author":"Asdaq","year":"2022","journal-title":"PeerJ"},{"key":"10.1016\/j.jiph.2025.102873_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jiph.2025.102873_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J Biomed Sci"},{"issue":"6","key":"10.1016\/j.jiph.2025.102873_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14712598.2022.2078160","article-title":"Therapeutic monoclonal antibodies for COVID-19 management: an update","volume":"22","author":"Chavda","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.jiph.2025.102873_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jiph.2025.102873_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112107","article-title":"Recent advances in management of COVID-19: a review","volume":"143","author":"Mouffak","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.jiph.2025.102873_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2032911","article-title":"Tocilizumab in Covid-19","volume":"384","author":"Leaf","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2025.102873_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108384","article-title":"Tocilizumab in critically ill COVID-19 patients: an observational study","volume":"102","author":"Mushtaq","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.jiph.2025.102873_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1753495X211056211","article-title":"A review of COVID-19 therapeutics in pregnancy and lactation","volume":"15","author":"Jorgensen","year":"2022","journal-title":"Obstet Med"},{"issue":"1","key":"10.1016\/j.jiph.2025.102873_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.26574\/maedica.2022.17.1.37","article-title":"Apprehension and stress associated with covid-19 pandemic - a population based study","volume":"17","author":"Sabir","year":"2022","journal-title":"Maedica"},{"issue":"6","key":"10.1016\/j.jiph.2025.102873_bib18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11596-021-2395-1","article-title":"A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics","volume":"41","author":"Forchette","year":"2021","journal-title":"Curr Med Sci"},{"issue":"2","key":"10.1016\/j.jiph.2025.102873_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/09638237.2021.1922636","article-title":"Risk perceptions, fear, depression, anxiety, stress and coping among Saudi nursing students during the COVID-19 pandemic","volume":"30","author":"Alsolais","year":"2021","journal-title":"J Ment Health"},{"issue":"6","key":"10.1016\/j.jiph.2025.102873_bib20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s00540-021-02974-0","article-title":"Tocilizumab in patients with COVID-19: which patient, time, and dose?","volume":"35","author":"Hasanin","year":"2021","journal-title":"J Anesth"},{"issue":"10","key":"10.1016\/j.jiph.2025.102873_bib21","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/10600280231218253","article-title":"Lecanemab: a humanized monoclonal antibody for the treatment of early Alzheimer disease","volume":"58","author":"Park","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jiph.2025.102873_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"Joshi","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.jiph.2025.102873_bib23","article-title":"The safety and efficacy of rituximab and belimumab in systemic lupus erythematosus: a systematic review","volume":"15","author":"Abid","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jiph.2025.102873_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s12890-023-02755-3","article-title":"The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials","volume":"23","author":"Daei Sorkhabi","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.jiph.2025.102873_bib25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13054-023-04561-z","article-title":"Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Wu","year":"2023","journal-title":"Crit Care"},{"key":"10.1016\/j.jiph.2025.102873_bib26","first-page":"1","article-title":"The ethics of publicly available data research: a situated ethics framework for reddit","volume":"2023","author":"Gliniecka","year":"2023","journal-title":"Sage J Soc Media Soc"},{"issue":"14","key":"10.1016\/j.jiph.2025.102873_bib27","article-title":"Chemical and biological strategies for profiling protein-protein interactions in living cells","volume":"18","author":"Wang","year":"2023","journal-title":"Chem Asian J"},{"issue":"3","key":"10.1016\/j.jiph.2025.102873_bib28","article-title":"Comparative efficacy of non-invasive therapies in temporomandibular joint dysfunction: a systematic review","volume":"16","author":"Alowaimer","year":"2024","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.jiph.2025.102873_bib29","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.cell.2024.03.038","article-title":"Exploring new perspectives in immunology","volume":"187","author":"Medzhitov","year":"2024","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jiph.2025.102873_bib30","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jaci.2020.07.008","article-title":"Emerging treatments in COVID-19: adverse drug reactions including drug hypersensitivities","volume":"146","author":"Manjaly Thomas","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jiph.2025.102873_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.iac.2022.10.005","article-title":"Drug hypersensitivity reactions","volume":"43","author":"Wilkerson","year":"2023","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.jiph.2025.102873_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820959183","article-title":"Tocilizumab and liver injury in patients with COVID-19","volume":"13","author":"Serviddio","year":"2020","journal-title":"Ther Adv Gastroenterol"},{"issue":"10","key":"10.1016\/j.jiph.2025.102873_bib33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.healun.2023.05.012","article-title":"Tocilizumab for antibody-mediated rejection treatment in lung transplantation","volume":"42","author":"January","year":"2023","journal-title":"J Heart Lung Transpl"},{"issue":"3","key":"10.1016\/j.jiph.2025.102873_bib34","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/mr\/road068","article-title":"Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: a subgroup analysis of a global, randomised, controlled Phase 3 trial","volume":"34","author":"Kuwana","year":"2024","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.jiph.2025.102873_bib35","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/rheumatology\/kead387","article-title":"Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study","volume":"63","author":"Wang","year":"2024","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jiph.2025.102873_bib36","first-page":"239","article-title":"Monoclonal antibodies for COVID-19 treatment: is it an option in Indonesia?","volume":"55","author":"Widhani","year":"2023","journal-title":"Acta Med Indones"},{"issue":"1","key":"10.1016\/j.jiph.2025.102873_bib37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7150\/thno.49713","article-title":"Immunopathogenesis and treatment of cytokine storm in COVID-19","volume":"11","author":"Kim","year":"2021","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.jiph.2025.102873_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14793","article-title":"Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis","volume":"30","author":"Ruan","year":"2024","journal-title":"CNS Neurosci Ther"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125002229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125002229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T23:53:03Z","timestamp":1762559583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034125002229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1876034125002229"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102873","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of tocilizumab in COVID-19: A systematic evaluation of adverse effects and therapeutic outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"102873"}}